Significant Unmet Clinical Need

Despite new medications, little progress has been made in developing new diagnostic and monitoring technologies for respiratory diseases such as asthma. Today’s standard of care is characterized by products, technologies and procedures that have not changed significantly in decades — such as spirometers. These technologies offer little insight for clinicians to make better clinical decisions for their patients in terms of initial diagnosis and continuous monitoring of asthmatic conditions. In terms of diagnosis of asthma, large numbers of asthmatics go untreated: 50% of children, and 33% of adults. Regarding monitoring, there are no solid-state devices to measure airway inflammation on a continuous basis.

New Standard of Care

Spirosure's Fractional exhaled Nitric Oxide (FeNO) breath analyzers are based on a patent-protected, solid-state sensor. Combining advanced materials with proprietary algorithms, the Spirosure sensor provides high sensitivity in its ability to detect very small particle concentrations. The patient exhales at a slow rate for 10 seconds to generate results in less than one minute. The point-of-care Fenom™ product is being designed to be used in the Allergist, General Practioner, Immunologist or Pulmonologist’s office. The at-home Fenomy™ product is being designed as a consumer device used by the patient directly, and on a regular basis as required. These devices include a digital ecosystem that will connect patients and clinicians and allow for better clinical decisions.

Global Market

Spirosure's patented solid-state sensor platform technology is the gateway to a wide range of healthcare’s largest global diseases and conditions, and systems to treat them. If a disease generates an exhaled biomarker, Spirosure's sensors will measure it. Our first target market is respiratory illness, with five pipeline diseases overall: asthma, COPD, lung cancer, heart failure, and metabolic diseases.

Source: United States Centers for Disease Control and Prevention (CDC)